Document is current
Any future updates will be listed below
-
Authors
Qin, Qian
Jun, Tomi
Wang, Bo
Patel, Vaibhav G.
Mellgard, George
Zhong, Xiaobo
Gogerly-Moragoda, Mahalya
Parikh, Anish B.
Leiter, Amanda
Gallagher, Emily J.
Alerasool, Parissa
Garcia, Philip
Joshi, Himanshu
MBBS,
Galsky, Matthew
Oh, William K.
Tsao, Che-Kai
- License Information
-
More Information
Article History
Received: 13 April 2022
Accepted: 2 August 2022
First Online: 12 August 2022
Declarations
:
: Data collection for this retrospective study was approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai.
: Qian Qin, MD, Tomi Jun, MD, Bo Wang, MD, Vaibhav G. Patel, MD, George Mellgard, BA, Xiaobo Zhong, DrPH, Mahalya Gogerly-Moragoda, BS, Anish B. Parikh, MD, Amanda Leiter, MD, Emily J. Gallagher, MD, Parissa Alerasool, BS, Philip Garcia, BS, and Joshi Himanshu, MBBS, PhD report no relevant financial or non-financial interests to disclose. William K. Oh, MD has consulting or advisory role with Astellas, AstraZeneca, Bayer, Foundry, Janssen, Sanofi, Sema4, and TeneoBio. Matthew Galsky, MD has stocks and ownership interest in Rappta Therapeutics, consulting or advisory role with BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, and Dragonfly Therapeutics, research funding from Janssen Oncology, Dendreon, Novartis, Bristol-Myers, Squibb, Merck, AstraZeneca, and Genentech/Roche, patents/royalties/other intellectual property with Methods and Compositions for Treating Cancer and Related Methods. Mount Sinai School of Medicine. July 2012 Application number: 20120322792.
